Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Refining diagnosis of multiple sclerosis with revised MRI criteria.
Chronic cladribine administration increases amyloid Beta Peptide generation and plaque burden in mice.
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Oracle Cladribine in Early Multiple Sclerisis (MS) (ORACLE MS)
Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
Intas launches biosimilar version of Rituximab
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mitoxantrone-related acute leukemia in MS: An open or closed book?
Genzyme provides update on U.S. LEMTRADA™ filing
A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA).
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review
IFN-β inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis.
Multiple Sclerosis and Pregnancy: Current Considerations.
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Genmab announces results of ofatumumab Phase II study in multiple sclerosis
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review
One can prevent post-partum MS relapses by exclusive breast feeding: no.
Rituximab and multiple sclerosis.
RTL therapy for multiple sclerosis: a Phase I clinical study.
Interferon beta for secondary progressive multiple sclerosis.

Pages